**Supporting Information – Table S1**

**Pentacyclic nitrofurans with *in vivo* efficacy and activity against latent *Mycobacterium tuberculosis***

Rakesh,1† David F. Bruhn,1† Michael S. Scherman,2 Lisa K. Woolhiser,2 Dora B. Madhura,3 Marcus M. Maddox,1 Aman P. Singh,1,4 Robin B. Lee,1 Julian G. Hurdle,1‡ Michael R. McNeil,2 Anne J. Lenaerts,2 Bernd Meibohm,3 Richard E. Lee1,4\*

1 Department of Chemical Biology and Therapeutics, St. Jude Children’s Research Hospital, Memphis, TN, USA

2 Mycobacterial Research Laboratories, Department of Microbiology, Colorado State University, Fort Collins, CO, USA

3 Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA

4 Biomedical Sciences Program, Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, TN, USA

‡ Present address: Department of Biology, University of Texas Arlington, Arlington, TX, USA  
\* [Richard.Lee@StJude.org](mailto:Richard.Lee@StJude.org) to whom all correspondence should be addressed.

† These authors contributed equally.

**Table S1: Spectrum of Activity**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Minimum Inhibitory Concentration (µg/mL) | | | | | | | | | | |
| Compound | *S.a*a | MRSA | *B.s.* | *S. Py.* | *S. Pn.* | *E.f.* | *B.a.* | *B.c.* | *S.m.* | *E.c.* | *E.c. ΔtolC* |
| **9a** b | 50 | 50 | 100 | 200 | 100 | >200 | 12.5 | 50 | 25 | >200 | 50 |
| **9b** | 200 | 200 | >200 | 200 | 200 | >200 | 50 | 100 | 100 | >200 | >200 |
| **9c** | >200 | >200 | 200 | 200 | >200 | >200 | 12.5 | >200 | >200 | >200 | >200 |
| **9d** | 6.3 | 100 | 100 | >200 | >200 | >200 | >200 | 50 | 6.3 | >200 | >200 |
| **9e** | >200 | 50 | 50 | >200 | >200 | 50 | >200 | 50 | 6.3 | >200 | >200 |
| **9f** | 3.13 | 12.5 | 25 | 50 | 25 | 6.3 | >200 | 12.5 | >200 | >200 | 12.5 |
| PA-824 | >200 | >200 | 200 | >200 | >200 | >200 | >200 | >200 | >200 | >200 | >200 |

*aOrganisms abbreviated above are as follows: S.a., Staphylococcus aureus (ATCC 29213); MRSA, Staphylococcus aureus (NRS70); B.s., Bacillus subtilis (ATCC 23857); S.py, Streptococcus pyogenes (ATCC 700294); S.pn, Streptococcus pneumoniae (R6); E.f., Enterococcus faecalis (ATCC 33186); B.a., Bacillus anthracis sterne 34F2; B.c., Burkholderia cepacia (ATCC 25416); S.m., Stenotrophomonas maltophilia (ATCC 13637); E.c., Escherichia coli (ATCC 700926); E.c. ∆tolC,E. coli K12 ∆tolC. bCompound 9a was inactive (MIC > 200 µg/mL) against Proteus mirabilis(ATCC 25933); Proteus vulgaris (ATCC 33420); Klebsiella pneumoniae (ATCC 33495); Acinetobacter baumannii (ATCC 19606); and Pseudomonas aeruginosa (PA01)1 are >200.*